Patient-Centered Opioid Tapering Study
NCT03303209 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51
Last updated 2025-12-22
Summary
This is an observational study of a voluntary opioid tapering protocol conducted in community outpatients taking long term prescription opioids for chronic pain. Patients who would otherwise continue with their existing opioid prescriptions were encouraged to participate in a voluntary opioid taper program. Interested patients were identified by their pain physician, Dr. Richard Stieg, and then completed an online informed consent document and baseline self-report assessments including types and doses of opioid medications as well as demographic and psychosocial measures, clinical and pain characteristics. Patients were either given or mailed a free copy of a patient book The Opioid-Free Pain Relief Kit, or Less Pain, Fewer Pills: Avoid the dangers of prescription opioids and gain control over chronic pain. Over the following weeks and up to 4 months, Dr. Stieg implemented a slow, individually tailored opioid taper in all patient participants. Follow-up online self-report surveys were completed at 4 months post enrollment. Opioid dose data were confirmed via medical chart review, and doses were converted to a standardized morphine equivalent daily dose (MEDD). Main outcome was change in opioid dose baseline to 4 months. Secondary outcome was change in pain intensity (numeric rating scale, 0-10) baseline to 4 months.
Conditions
- Opioid Use
- Chronic Pain
Interventions
- OTHER
-
Patient-centered opioid tapering protocol
All patients who entered the study agreed to partner with their pain physician on a patient-centered opioid tapering program. The research component of the study was to observe patient response (in terms of change in MEDD and pain intensity) at month 4.
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Beth Darnall, PhD · Stanford University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-09-15
- Primary Completion
- 2017-08-10
- Completion
- 2017-08-10
More Related Trials
-
Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain
NCT01081912 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2 Chronic Low Back Pain Study
NCT01364922 ·Status: COMPLETED ·Phase: PHASE2
-
Cognitive Behavioral Therapy and Chronic Pain Self-Management Within the Context of Opioid Reduction: The EMPOWER Study
NCT03445988 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain
NCT00364546 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Trial Comparing Oxycodone Medications
NCT01162304 ·Status: TERMINATED ·Phase: PHASE4
-
An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)
NCT01631513 ·Status: WITHDRAWN ·Phase: PHASE4
-
Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain
NCT01115569 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
NCT00983385 ·Status: COMPLETED ·Phase: PHASE3
-
Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.
NCT01838616 ·Status: COMPLETED ·Phase: PHASE4
-
Long-term Safety of PF-00345439 (Oxycodone)
NCT01559701 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
NCT01100320 ·Status: COMPLETED ·Phase: PHASE1
-
Evolution of Analgesic Tolerance With Opioids
NCT00275249 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine
NCT00472303 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain
NCT01789970 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
NCT00487435 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain
NCT00361504 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety
NCT00364533 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
NCT01099709 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions
NCT02089295 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
NCT01100086 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Pharmacokinetic Study of Tapentadol Prolonged-Release 250 Milligram (mg) Formulation in Healthy Participants
NCT01877226 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
NCT01101191 ·Status: COMPLETED ·Phase: PHASE1
-
Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis
NCT00771758 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets
NCT01922739 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time
NCT01223365 ·Status: COMPLETED ·Phase: PHASE3